• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53.人甲状腺癌细胞作为具有或不具有功能性p53的同基因、同表型细胞系的来源。
Br J Cancer. 1999 Mar;79(7-8):1111-20. doi: 10.1038/sj.bjc.6690177.
2
Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells.人钠/碘同向转运体基因启动子在甲状腺乳头状癌细胞系和正常甲状腺细胞中的差异调控
Endocrinology. 2001 Aug;142(8):3369-79. doi: 10.1210/endo.142.8.8344.
3
p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells.p53基因的重新表达可抑制人甲状腺未分化癌细胞的增殖并恢复其分化。
Oncogene. 1997 Feb 13;14(6):729-40. doi: 10.1038/sj.onc.1200887.
4
Reexpression of thyroid peroxidase in a derivative of an undifferentiated thyroid carcinoma cell line by introduction of wild-type p53.通过导入野生型p53使未分化甲状腺癌细胞系衍生物中甲状腺过氧化物酶重新表达。
Cancer Res. 1996 Feb 15;56(4):765-71.
5
P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression.甲状腺乳头状癌和间变性癌中p63的表达:在肿瘤发生和进展中缺乏致癌作用
Pathol Res Pract. 2002;198(7):449-54. doi: 10.1078/0344-0338-00281.
6
Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.有证据表明,一部分间变性甲状腺癌是由于BRAF和p53突变而由乳头状癌演变而来。
Cancer. 2005 Jun 1;103(11):2261-8. doi: 10.1002/cncr.21073.
7
All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1.
J Clin Endocrinol Metab. 2000 Aug;85(8):2889-96. doi: 10.1210/jcem.85.8.6732.
8
A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3',5'-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells.人类钠/碘同向转运体基因中的一个甲状腺特异性远上游增强子需要Pax-8结合以及环磷酸腺苷反应元件样序列结合蛋白才能发挥完全活性,并且在正常细胞和甲状腺癌细胞中受到不同调控。
Mol Endocrinol. 2002 Oct;16(10):2266-82. doi: 10.1210/me.2002-0109.
9
A mutated p53 gene alters thyroid cell differentiation.一个突变的p53基因会改变甲状腺细胞的分化。
Oncogene. 1995 Nov 16;11(10):2029-37.
10
Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells.辐射诱导的G1期阻滞在人甲状腺细胞中由p53-WAF1/Cip1途径选择性介导。
Cancer Res. 1995 May 15;55(10):2075-80.

引用本文的文献

1
(99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.用于成像低分化转移性甲状腺癌的(99m)锝标记重组人促甲状腺素类似物(TR1401)
Thyroid. 2014 Aug;24(8):1297-308. doi: 10.1089/thy.2013.0429. Epub 2014 Jun 20.
2
The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells.PTTG1 结合因子(PBF/PTTG1IP)调节甲状腺细胞中的 p53 活性。
Endocrinology. 2014 Apr;155(4):1222-34. doi: 10.1210/en.2013-1646. Epub 2014 Feb 7.
3
PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein.PAX8 通过转录调控 E2F1 和稳定 RB 蛋白促进肿瘤细胞生长。
Oncogene. 2011 Dec 1;30(48):4824-34. doi: 10.1038/onc.2011.190. Epub 2011 May 23.
4
Tissue-selective therapy of cancer.癌症的组织选择性治疗。
Br J Cancer. 2003 Oct 6;89(7):1147-51. doi: 10.1038/sj.bjc.6601256.
5
Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin.人乳头瘤病毒16型感染皮肤中朗格汉斯细胞的耗竭与E6介导的E-钙黏蛋白下调有关。
J Virol. 2003 Aug;77(15):8378-85. doi: 10.1128/jvi.77.15.8378-8385.2003.
6
Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress.在经历低剂量紫杉醇诱导的有丝分裂应激的人类淋巴瘤细胞中凋亡的延迟表达。
Br J Cancer. 2003 May 19;88(10):1649-58. doi: 10.1038/sj.bjc.6600905.

本文引用的文献

1
Molecular genetics of thyroid cancer.甲状腺癌的分子遗传学
Trends Endocrinol Metab. 1993 Sep;4(7):224-32. doi: 10.1016/1043-2760(93)90126-y.
2
Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.美国国立癌症研究所抗癌药物筛选细胞系中p53肿瘤抑制通路的特征以及与123种抗癌药物生长抑制效力的相关性
Cancer Res. 1997 Oct 1;57(19):4285-300.
3
An information-intensive approach to the molecular pharmacology of cancer.一种针对癌症分子药理学的信息密集型方法。
Science. 1997 Jan 17;275(5298):343-9. doi: 10.1126/science.275.5298.343.
4
The tumour suppressor gene p53 as a regulator of proliferative life-span and tumour progression.
Biol Signals. 1996 May-Jun;5(3):139-53. doi: 10.1159/000109184.
5
Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression?
Int J Cancer. 1996 Aug 7;67(4):563-72. doi: 10.1002/(SICI)1097-0215(19960807)67:4<563::AID-IJC16>3.0.CO;2-8.
6
A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.一种能区分p53反应基因的突变型p53无法诱导细胞凋亡。
Mol Cell Biol. 1996 Sep;16(9):4961-71. doi: 10.1128/MCB.16.9.4961.
7
Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.具有受损凋亡功能的p53突变体对靶细胞启动子的差异性激活。
Mol Cell Biol. 1996 Sep;16(9):4952-60. doi: 10.1128/MCB.16.9.4952.
8
Interference with p53 protein inhibits hematopoietic and muscle differentiation.对p53蛋白的干扰会抑制造血和肌肉分化。
J Cell Biol. 1996 Jul;134(1):193-204. doi: 10.1083/jcb.134.1.193.
9
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.人低分化甲状腺癌中p53基因突变的高发生率。
J Clin Invest. 1993 Jan;91(1):179-84. doi: 10.1172/JCI116168.
10
Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.p53基因剂量的减少不会增加化学诱导皮肤肿瘤的起始或促进阶段,但会增强其恶性进展。
Cell. 1993 Sep 10;74(5):813-22. doi: 10.1016/0092-8674(93)90461-x.

人甲状腺癌细胞作为具有或不具有功能性p53的同基因、同表型细胞系的来源。

Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53.

作者信息

Wyllie F S, Haughton M F, Rowson J M, Wynford-Thomas D

机构信息

Department of Pathology, University of Wales College of Medicine, Cardiff, UK.

出版信息

Br J Cancer. 1999 Mar;79(7-8):1111-20. doi: 10.1038/sj.bjc.6690177.

DOI:10.1038/sj.bjc.6690177
PMID:10098744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2362227/
Abstract

Differentiated thyroid carcinomas (in contrast to the rarer anaplastic form) are unusual among human cancers in displaying a remarkably low frequency of p53 mutation and appear to retain wild-type (wt) p53 function as assessed by the response of derived cell lines to DNA damage. Using one such cell line, K1, we have tested the effect of experimental abrogation of p53 function by generating matched sub-clones stably expressing either a neo control gene, a dominant-negative mutant p53 (143ala) or human papilloma virus protein HPV16 E6. Loss of p53 function in the latter two groups was confirmed by abolition of p53-dependent 'stress' responses including induction of the cyclin/CDK inhibitor p21WAF1 and G1/S arrest following DNA-damage. In contrast, no change was detected in the phenotype of 'unstressed' clones, with respect to any of the following parameters: proliferation rate in monolayer, serum-dependence for proliferation or survival, tumorigenicity, cellular morphology, or tissue-specific differentiation markers. The K1 line therefore represents a 'neutral' background with respect to p53 function, permitting the derivation of functionally p53 + or - clones which are not only iso-genic but also iso-phenotypic. Such a panel should be an ideal tool with which to test the p53-dependence of cellular stress responses, particularly the sensitivity to potential therapeutic agents, free from the confounding additional phenotypic differences which usually accompany loss of p53 function. The results also further support the hypothesis that p53 mutation alone is not sufficient to drive progression of thyroid cancer to the aggressive anaplastic form.

摘要

分化型甲状腺癌(与罕见的未分化型不同)在人类癌症中较为特殊,其p53突变频率极低,并且从衍生细胞系对DNA损伤的反应来看,似乎保留了野生型(wt)p53功能。利用其中一种细胞系K1,我们通过构建稳定表达新霉素对照基因、显性负性突变体p53(143ala)或人乳头瘤病毒蛋白HPV16 E6的匹配亚克隆,测试了实验性消除p53功能的效果。后两组中p53功能的丧失通过消除p53依赖性“应激”反应得以证实,包括细胞周期蛋白/周期蛋白依赖性激酶抑制剂p21WAF1的诱导以及DNA损伤后的G1/S期阻滞。相比之下,在“未受应激”的克隆中,未检测到以下任何参数的变化:单层增殖率、增殖或存活的血清依赖性、致瘤性、细胞形态或组织特异性分化标志物。因此,K1细胞系在p53功能方面代表了一个“中性”背景,允许衍生出功能上p53阳性或阴性的克隆,这些克隆不仅是同基因的,而且是同表型的。这样一组克隆应该是测试细胞应激反应对p53依赖性的理想工具,特别是对潜在治疗药物的敏感性,而不受通常伴随p53功能丧失的额外表型差异的干扰。这些结果也进一步支持了以下假说,即仅p53突变不足以促使甲状腺癌发展为侵袭性未分化型。